Jun 27, 2019   SOURCE: PR NewsWire

Letairis (ambrisentan; Gilead/GlaxoSmithKline) Market to 2025: A Selective Endothelin Type A Receptor Antagonist

DUBLIN, June 27, 2019 /PRNewswire/ -- The "Letairis" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Letairis (ambrisentan; Gilead/GlaxoSmithKline) is a selective endothelin type A receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory properties. By preventing endothelin from binding to the endothelin receptor, Letairis blocks the receptor-mediated vasoconstriction of vascular smooth muscle cells.

Analyst Outlook

While second-to-market Letairis (ambrisentan; Gilead/GlaxoSmithKline) has not managed to exceed the historical peak sales of fellow endothelin receptor antagonist (ERA) Tracleer (bosentan; Johnson & Johnson), it has remained a market-leading drug. Given that Letairis will imminently face generic competition in the US in October 2018, with other markets shortly following, the drug has limited opportunities for further uptake within the pulmonary hypertension (PH) market.

Nonetheless, Letairis is expected to continue to benefit from the increasing adoption of ERAs in combination with phosphodiesterase 5 (PDE5) inhibitors based on the AMBITION trial. This will counterbalance some generic erosion and aid in maintaining steady sales despite intensifying competition.

Key Topics Covered:

OVERVIEW

    --  Drug Overview
    --  Product Profiles

LIST OF FIGURES

    --  Letairis: Pulmonary hypertension
    --  Letairis for pulmonary hypertension - SWOT analysis
    --  The authors drug assessment summary of Letairis for pulmonary
        hypertension
    --  Letairis sales for pulmonary hypertension across the US, Japan, and five
        major EU markets, by country, 2016-25

LIST OF TABLES

    --  Letairis drug profile
    --  Letairis pivotal trial data in pulmonary arterial hypertension
    --  Letairis sales for pulmonary hypertension across the US, Japan, and five
        major EU markets, by country ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/5vbzfl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/letairis-ambrisentan-gileadglaxosmithkline-market-to-2025-a-selective-endothelin-type-a-receptor-antagonist-300876053.html

SOURCE Research and Markets